AI Article Synopsis
- Metabolic disorders like diabetes, obesity, and heart disease are major global health challenges, and this study investigates the effects of a nutraceutical called SB, which is rich in polyphenols, on these conditions in animal models.
- A thorough review and meta-analysis of existing studies showed that SB significantly lowers blood glucose levels in diabetic animals, particularly noted in acute treatments.
- While SB shows promise for improving metabolic health, the variability in results points to the need for more consistent studies and clinical trials to fully understand its benefits and mechanisms.
Article Abstract
Background/objectives: Metabolic disorders, including diabetes, obesity, and cardiovascular diseases, are significant global health issues. Nutraceuticals, such as (SB), known for its high polyphenol content, are increasingly explored for managing these conditions. This study aims to evaluate the antihyperglycemic, hypolipidemic, and antihypertensive effects of SB in animal models to understand its potential as a natural intervention for metabolic diseases.
Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. Searches across databases like PubMed, Web of Science, Embase, and Scopus identified studies using SB in animal models of metabolic disorders. Inclusion criteria were studies with SB intervention, control groups, and quantitative measures of metabolic parameters. The study was registered with INPLASY (INPLASY2024100031).
Results: The meta-analysis revealed that SB significantly reduces blood glucose levels in diabetic animal models. Acute administration of SB showed a pooled standardized mean difference (SMD) of -7.13 (95% CI: -11.44 to -2.83) at 1 h and -9.75 (95% CI: -15.92 to -3.59) at 2-4 h post-administration. Chronic administration indicated a non-significant reduction in glucose levels (SMD: -5.69, 95% CI: -16.38 to 5.01).
Conclusions: SB appears to have the potential for reducing blood glucose levels and may offer benefits for other cardiometabolic risk factors, including lipid profiles and oxidative stress. However, variability in the results underscores the need for further research, including standardized animal studies and clinical trials, to confirm these effects and clarify the mechanisms by which SB may impact metabolic disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11596559 | PMC |
| http://dx.doi.org/10.3390/metabo14110615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!